| Autor: |
Cerbelli, Bruna, Cirillo, Alessio, Pomati, Giulia, Pernazza, Angelina, Ascione, Andrea, Pisegna, Simona, Pisano, Annalinda, Leopizzi, Martina, Pignataro, Maria Gemma, Costarelli, Leopoldo, Mulè, Antonino, Vecchione, Andrea, Catalano, Piera, Coppola, Luigi, Perrone, Giuseppe, Perracchio, Letizia, Anemona, Lucia, Mastracchio, Antonio, Nardi, Stefano, Reitano, Renato, Massari, Annalisa, Grillo, Lucia Rosalba, Liberati, Fabrizio, Della Rocca, Carlo, Marchetti, Paolo, Botticelli, Andrea, D’Amati, Giulia |
| Zdroj: |
Tumori Journal; February 2024, Vol. 110 Issue: 1 p44-48, 5p |
| Abstrakt: |
Background: Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period.Methods: The survey comprised 12 questions regarding the availability of SP142 in the pathology departments, the percentage of positive tests, the difficulties of pathologists in cases close to cut-off value and the tested samples.Results: The SP142 assay was available in only eight centers. In case of positive result, most centers (5/8, 62.5%) reported values of PD-L1 expression ranging from > 1 to ⩽ 5%, with values close to the cut-off point (⩾ 1% or < 1%) being the greatest challenge. Most of the centers (6/8, 75%) tested material from both their own and other hospitals. In most centers, the evaluations were performed either on primary tumors or metastasis, in particular lymph nodes (5/8, 62.5%), followed by lung (3/8, 37.5%) and liver (1/8, 12.5%) metastasis.Conclusion: Our results raise some important issues concerning the evaluation of PD-L1 in the “real-life” setting, providing strategies for its implementation. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
